Phase 3 Development of Resmetirom: a Liver-Directed Thyroid Hormone Receptor (THR)-Beta Agonist for the Treatment of Patients with NASH and Significant Liver Fibrosis (as presented at EASL 2021)
Click icon in video above (bottom right) for full-screen
Please click below to view Presentations
Please become a Melody.education Member to watch this program and receive updates on future programs
Vlad Ratziu, MD, PhD
Hôpital Pitié - Salpêtrière
Institute of Cardiometabolism and Nutrition Paris, France
Vlad Ratziu is a Professor of Hepatology at Sorbonne University, and performs his hospital work at the Pitié-Salpêtrière Hospital and the Institute for Cardiometabolism and Nutrition (ICAN) in Paris, France. Professor Ratziu received his medical training at Paris Descartes University; he then completed a 2-year postdoctoral fellowship at the Liver Center at the University of California, San Francisco, CA, USA, and went on to earn a doctoral degree from Paris Diderot University for his work on the pathophysiology of viral and metabolic liver fibrosis.
Professor Ratziu’s main research interests are in the field of non-alcoholic fatty liver disease (NAFLD); the mechanisms, risk factors, and progression of liver fibrosis in viral and metabolic diseases; and the treatment of viral hepatitis and hepatocellular carcinoma. He coordinated or participated in several therapeutic trials in NASH. He was also involved in different European financed FP7, Horizon 2020 and Innovative Medicines Initiative 2 consortia. He is a member of the organising committee of the NASH–TAG meetings. He is a Co-Editor for the Journal of Hepatology and an associate editor for Clinical Liver Disease. He has published more than 300 articles in top-tier specialty journals.